logo

For the Inventor, By the Inventor

Hull, United Kingdom

Indivior UK Limited


USPTO Granted Patents = 38

% Expired Patents = 5.3



Trademarks = 31

Forward Citations = 157

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Richard L Norton (13 out of 33 patents)

silverMedal Mingxing Zhou (11 out of 17 patents)

bronzeMedal Andrew Watkins (10 out of 12 patents)

4.  Eric Dadey (8 out of 22 patents)

5.  Qi Li (6 out of 6 patents)

6.  Fabrizio Micheli (6 out of 34 patents)

7.  Luca Tarsi (6 out of 16 patents)

8.  Susanna Cremonesi (5 out of 9 patents)

9.  Teresa Semeraro (5 out of 8 patents)

10.  Christopher M Lindemann (4 out of 11 patents)

11.  Celine M Laffont (4 out of 4 patents)

12.  Guohua Chen (3 out of 42 patents)

13.  Andrew S Luk (3 out of 14 patents)

14.  Gunjan H Junnarkar (3 out of 13 patents)

15.  Azmi Nasser (3 out of 3 patents)


Core Competencies:
Buprenorphine
Opioid Overdose
Sustained Release
Dopamine Receptor Antagonists
Therapeutic Compounds
Injectable Composition
Dosing Regimens
Sublingual Film
Hydrogel Inclusion Complex
Flowable Composition
Risperidone Formulations
Opioid Use Disorder

38 patents:

1. 12622904 - Buprenorphine dosing regimens (2026-05-12),
2. 12441709 - Therapeutic compounds (2025-10-14),
3. 12290596 - Compositions and methods for the treatment of opioid overdose (2025-05-06),
4. 11857498 - Syringe system (2024-01-02),
5. 11839611 - Buprenorphine dosing regimens (2023-12-12),
6. 11712475 - Sustained delivery formulations of risperidone compound (2023-08-01),
7. 11478407 - Syringe system (2022-10-25),
8. 11135216 - Sublingual and buccal film compositions (2021-10-05),
9. 11110093 - Sustained release small molecule drug formulation (2021-09-07),
10. 11013809 - Sustained delivery formulations of risperidone compound (2021-05-25),
11. 11000520 - Buprenorphine dosing regimens (2021-05-11),
12. 10654842 - Dopamine Dreceptor antagonist compounds (2020-05-19),
13. 10646484 - Methods to treat opioid use disorder (2020-05-12),
14. 10592168 - Injectable flowable composition comprising buprenorphine (2020-03-17),
15. 10584135 - Substituted 3,6-diazabicyclo[3.2.0]heptanes (2020-03-10),
Company Overview
Indivior UK Limited is a global pharmaceutical company headquartered in Hull, UK, specializing in the development and commercialization of innovative treatments for addiction and related disorders. The company focuses on addressing the needs of individuals affected by opioid dependence and other substance use disorders through advanced therapeutic solutions. With a commitment to research and development, Indivior aims to improve patient outcomes and support recovery through its specialized healthcare offerings.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Indivior UK Limited USPTO Patent Assignee Logo
38 Patents

#2 in Hull

#471 in United Kingdom

#17,844 in the World

Hull, GB
Hull, United Kingdom

Indivior UK Limited

Forward Citations = 157

34 inventors:

goldMedal Richard L Norton (13 out of 33 patents)

silverMedal Mingxing Zhou (11 out of 17 patents)

bronzeMedal Andrew Watkins (10 out of 12 patents)

4.  Eric Dadey (8 out of 22 patents)

5.  Qi Li (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Indivior UK Limited. Retrieved from https://idiyas.com/company/indivior-uk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…